Welcome to our dedicated page for BELLRING BRANDS SEC filings (Ticker: BRBR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BellRing Brands, Inc. filings document financial results, governance actions and capital-allocation disclosures for a public nutrition-products company. Its 8-K reports include quarterly and fiscal-year earnings releases, supplemental presentations, outlook updates, share repurchase authorizations and Regulation FD materials related to company communications.
Proxy and governance filings cover annual meeting matters, director elections, auditor ratification, executive compensation votes, board composition and committee assignments. Other Item 5.02 disclosures record executive-compensation arrangements and leadership-transition matters, while exhibits and Inline XBRL cover pages provide the formal record for material events reported under the Exchange Act.
BellRing Brands (BRBR) Q3 FY25 (ended 6/30/25) 10-Q highlights
- Sales growth but profit hit: Net sales rose 6% YoY to $547.5 m, led by Premier Protein (+6%) and Dymatize (+5%). However, a $68.1 m litigation provision pushed SG&A to $144.5 m, slashing operating profit 60% to $44.8 m and diluted EPS 71% to $0.16.
- Margin pressure: Gross margin slipped 140 bp to 35.4% on higher raw-material and manufacturing costs. Operating margin fell from 21.7% to 8.2%.
- Nine-month view: Revenue up 16% to $1.67 bn, but EPS down 8% to $1.21 as inflation and legal costs offset volume gains.
- Balance-sheet shifts: Inventories +45% YoY to $415.6 m; cash down 38% to $43.7 m. Debt increased to $1.01 bn after $175 m revolver draw; net leverage covenant remains <6×.
- Capital returns: Repurchased 3.8 m shares for $267.6 m YTD; treasury stock now $566.6 m.
- Legal overhang: Total accrual for Joint Juice litigation raised to $90 m; class-wide settlement in principle reached, pending court approval.
- Cash flow: Operating cash fell 43% to $91.5 m, mainly from inventory build and higher receivables.
- Outlook items: Management cites continuing input-cost inflation and is evaluating July 2025 U.S. tax law changes; no quantitative guidance provided.